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ABSTRACT: Adenosine receptors are involved in many
pathological conditions and are thus promising drug targets.
However, developing drugs that target this GPCR subfamily is a
challenging task. A number of drug candidates fail due to lack of
selectivity which results in unwanted side eﬀects. The extensive
structural similarity of adenosine receptors complicates the
design of selective ligands. The problem of selective targeting is
a general concern in GPCRs, and in this respect adenosine
receptors are a prototypical example. Here we use enhanced
sampling simulations to decipher the determinants of selectivity
of ligands in A2a and A1 adenosine receptors. Our model shows how small diﬀerences in the binding pocket and in the water
network around the ligand can be leveraged to achieve selectivity.
■ INTRODUCTION
Adenosine receptors are Class A G-protein-coupled receptors
(GPCRs) that are widely expressed in neurons, immune
system cells, and vascular system.1 The adenosine signaling has
long been shown to regulate cytoprotective and immune
response in tissues.2 Of the four subtypes, A1R and A2aR have
received most attention from the scientiﬁc community, mainly
due to their therapeutic potential for the treatment of
reperfusion injury and neuropathic pain (A1R), cancer,
attention deﬁcit hyperactivity disorder (ADHD), and Parkin-
son’s Disease (PD) (A2aR).
3,4 Notwithstanding signiﬁcant
eﬀorts, the success in developing molecules with high potency
and selectivity has been limited.5 The proteins have a sequence
identity of 37%,6 with limited structural diﬀerences and
remarkably similar orthosteric binding pockets7−9 (Figure 1),
as all key pocket-lining residues are conserved with the
exception of the position 7.35 (Ballesteros-Weinstein number-
ing scheme,10 where the ﬁrst number refers to the trans-
membrane helix and the second to the position relative to the
most conserved residue of the helix, which is arbitrarily set to
50). The lack of diﬀerences in the pockets of the two receptors
poses a real challenge for the design of selective ligands.5
Thus, understanding how ZM241385, an A2aR-selective
inverse agonist, achieves its selectivity is of great importance.
To this aim we have recently solved and analyzed a new crystal
structure of the complex.11 However, the highly dynamical
nature of the receptors is not fully captured by the crystal
structures,11−14 leaving a number of questions unanswered. For
instance, while ZM241385 shows greatly reduced aﬃnity for
A1R, its dehydroxy derivative LUF5452
15 binds with the same
aﬃnity to the two proteins (Table 1). The two ligands are very
similar (Figure 2), and the crystallographic binding mode of
ZM241385 to A2aR shows that the only part of the ligand
diﬀering to LUF5452 does not form signiﬁcant direct
interactions with the receptor.11
The challenges of explaining the diﬀerential binding aﬃnities
of ligands based on static poses hints at an important role of
the binding mechanisms and perhaps diﬀerent ﬂexibility of the
receptors. Thus, to fully understand the determinants of
selectivity, the crystal structures need to be complemented by a
method that is able to reconstruct the binding process in
atomistic detail and provide information on the diﬀerent
dynamical properties of the receptors. To this end, here we use
molecular dynamics simulations (MD) combined with
enhanced sampling algorithms, that have been successfully
used to model ligand binding in GPCRs.11,16,17
■ RESULTS AND DISCUSSION
Interaction of the Ligands with the Binding Sites. To
elucidate the binding pose and the role of the interfacial water,
1 μs-long unbiased MD were run for human A1R and A2aR in
complex with either ZM241385 or LUF5452 starting with the
ligand bound to the binding site. An important diﬀerence in
the binding sites of the two receptors is constituted by the 7.35
position, T2707.35 in A1R and M270
7.35 in A2aR. Its role in
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determining the selectivity of ligands with bulky substituents
has been proposed in previous studies.9 Indeed, in our
simulations we observe a poorer stacking of the ligand cores in
A1R due to the smaller side chain of the threonine residue with
respect to the methionine of A2aR. Thus, while in A2aR the
ligands remained close to the initial pose (with two relatively
similar conformations), in A1R a signiﬁcant reorientation of the
(4-hydroxy)phenyl-ethyl tail was observed.
Of the two conformations adopted by the ligands in A2aR,
one is close to the starting crystallographic structure (PDB
5IU411), with the (4-hydroxy)phenyl-ethyl tail pointing toward
the extracellular side of the protein, and one is very similar to
the crystallographic structure of the thermostabilized receptor
(PDB 3PWH),13 with the tail pointing toward TM1. The
various conformations can be monitored using the RMSD of
the common heavy atoms of the two ligands (Figure 3). While
ZM241385 preferentially adopts the upright (5IU4-like)
position in the simulations, LUF5452 tends to explore
3PWH-like conformations. In this conformation, ZM241385
is able to form polar interactions with Y91.35, E131.39, and
A632.61. The interconversion of the poses has signiﬁcant eﬀect
on the hydration of the tail, with partial desolvation happening
for 3PWH-like states and allowing LUF5452 to minimize
unfavorable interactions between the solvent and the phenyl
ring, as seen in Figure 4. A hydrogen bond network involving
the ligands and water molecules stabilizes the molecules in the
pocket of A2aR (Figure 3, conformations a1 and b1), as is also
evident from crystallographic structures.11,12 Although the
cavity is wide enough for observing much movement of solvent
molecules, there is a tendency to adopt ordered patterns of
interaction, that are disrupted in 3PWH-like states. The
desolvation of the phenyl ring leads LUF5452 to frequently
adopt such conformations and leads to a poor arrangement of
water molecules, contributing to the lower aﬃnity for the
receptor with respect to ZM241385.
In A1R, the ligands are much more mobile. ZM241385 was
observed rotating the tail to a 3PWH-like conformation
(Figure 3, conformation c2) and temporarily interacting with
an hydrophobic cavity of the extracellular vestibule (ECV)
formed by ECL2 and the ends of the transmembrane helices
(TM) 2 and 3 (See Figure S1a). LUF5452 instead undergoes a
more signiﬁcant conformational rearrangement, rotating its
core away from the upright orientation and projecting the tail
toward the same pocket without reverting to the starting pose
(Figure 3, conformation d2). In this conformation the
hydrogen bond between the exocyclic primary amine of the
ligand and N2546.55 is broken to allow the phenyl ring of the
molecule to interact with the pocket. The distance between the
amine nitrogen of LUF5452 and the carbonyl oxygen of
N2546.55 increases from 3 to 6 Å. This results in a signiﬁcant
rearrangement of the interfacial water molecules (see Figure
S2). Similar to A2aR, adopting a 3PWH-like conformation
results in a partial desolvation (0.30 > ligand RMSD to 5IU4 >
0.45 nm in Figure 4). Moreover, the wide volume of the pocket
of A1R allows for the presence of a large number of solvent
molecules. While in this receptor the interactions of the tail of
ZM241385 with the solvent are stabilized by the hydroxy
group, LUF5452 is instead able to bury the phenyl ring in the
hydrophobic ECV pocket, leading to more eﬀective desolva-
tion than in A2aR (Figure 4B).
Binding Poses of the Ligands. To better quantify the
relative free energy of the diﬀerent poses, as well as to compute
the full free energy landscape associated with the binding of the
ligands, we run parallel tempering metadynamics simulations
(PT-metaD)19,20 on the four complexes. For A2aR, the chosen
collective variables (CVs) were the projection of the vector
connecting the binding pocket and the ligand onto the Z-axis
Figure 1. ZM241385 bound to the binding sites of (a) A2aR and (b)
A1R in the enhanced-sampling simulations. (c) The salt bridge
hindering the pocket entrance is shown as spheres. A zoomed view of
the ligands in the binding sites and the key residues is presented in the
boxes.
Table 1. Experimental and Calculated Binding Free Energy
of ZM241385 and LUF5452 to A1R and A2aR
a
A1R A2aR
ΔGexp ΔGcalc ΔGexp ΔGcalc
ZM241385 −9.05a,−
7.81b
−8.23 ± 0.73 −12.01a,−
12.90b
−11.87 ± 0.43
LUF5452 −11.19a −10.34 ± 0.27 −11.35a −10.57 ± 0.53
aExperimental aﬃnity data was obtained from de Zwart et al.15 and
Guo et al.21 and was converted with the relation ΔG = −RT ln(Ka).
Superscripts refer to the source organism: (a) rat or (b) human. Data
in kcal/mol.
Figure 2. Ligands in this study, ZM241385 and LUF5452.
Journal of Chemical Information and Modeling Article
DOI: 10.1021/acs.jcim.9b00298
J. Chem. Inf. Model. XXXX, XXX, XXX−XXX
B
(Z-projection) and onto the XY-plane (XY-projection) parallel
to the membrane. In A1R, extensive tests showed that
including the distance between the salt bridge-forming
residues, E172 and K265 speeds the convergence of the free
energy. Thus, for ZM241385, we used the distance and the Z-
projection, while for LUF5452 all three CVs were used (see
the Supporting Information).
The deepest free energy minimum for the two ligands
corresponds to the crystallographic binding pose of
ZM24138511,12 in A2aR and closely resemble it in A1R (Figure
5). As expected, the presence of the same key residues in the
pocket allows the molecules to form analogous interactions
and therefore adopt similar binding poses with respect to A2aR.
The binding free energy associated with the minima in all four
systems agrees well with experimental values (Table 1).
LUF5452 Interacts with the Accessory Hydrophobic
Site. As observed in the unbiased MD simulations, LUF5452
also shows an equally stable secondary minimum in which it
makes signiﬁcant contacts with the hydrophobic ECV pocket
of A1R (Figure 5). The interaction allows the ligand to rotate
away from the expected pose, breaking the hydrogen bond
between the exocyclic amine and the side chain of N2546.55
(Figure S1a). The region is lined by L652.60, A662.61, I692.64,
V833.28, A843.29, C169, E170, and F171. In this conformation,
the phenyl group of the ligand is nearly parallel to TM2 and is
positioned between the side chains of I692.64 and F171. The
ring of F171 is involved in a stacking interaction with the core
of the ligand and a T-shaped (quadrupolar) one with its phenyl
group. The presence of the aromatic ring of LUF5452 in the
pocket displaces a number of water molecules (Figure S1a).
Analysis of the pocket with the GRID software22 conﬁrms
the highly hydrophobic nature of its surface, with overlap
between the hotspot identiﬁed with the C1 (lipophilic,
carbon sp2 probe) and the phenyl ring of LUF5452 (Figure
S3).
As also observed in the unbiased MD, the hydrophobic
nature of the region makes the interaction with the solvent
unfavorable and displacing the “unhappy waters” increases the
strength of the interaction with the ligand stabilizing the
secondary minimum. The importance of exploiting the
presence of “unhappy waters” has been previously shown in
other GPCRs.23,24
Salt Bridge Inﬂuences Binding. In both proteins a salt
bridge is present at the entrance of the binding site, hindering
the binding and unbinding of the ligands. While in A2aR the
interaction is formed between the residues E169 and H264; in
A1R a lysine residue (K265) forms a stronger contact with
E172. The diﬀerent nature of the salt bridge in the two
receptors results in a much higher stability of the E172-K265
contact in A1R with respect to its counterpart in A2aR (Figure
S4a) and was reﬂected in the need to bias the distance between
the side chains in our metadynamics simulations of A1R. We
also ﬁnd that the strong salt bridge in A1R hinders the binding
and unbinding of the ligand (Figure 5). On the contrary, the
Figure 3. Analysis of the conformations adopted by ZM241385 and LUF5452 in the binding pocket of A2aR and A1R over the unbiased MD
simulation. Probability over the space deﬁned by the RMSD of the common heavy atoms of the ligands to the conformation adopted in PDB 5IU4
or 3PWH, after alignment to the backbone of the proteins. TM7 not shown for clarity.
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weaker salt bridge in A2aR has a smaller inﬂuence on the
binding dynamics.
The restriction of the cross-sectional area of the entrance of
the binding site determined by the helical turn of ECL2
hosting E169 (A2aR) or E172 (A1R) and ECL3 forces the
ligand to approach the salt bridge at a right angle between the
common core plane and the bridge axis. Generally, the
molecules initially interact with the residues with either the
furane ring or with the bicyclic region of the cores. In A2aR,
stacking of the core and the side chain of H264 is also
observed (Figure 5).
The importance of the salt bridge of A2aR for the binding
mechanism is supported by mutagenesis and structural
data11,25 and was previously suggested for A1R in the
literature.26
Dominant Binding Pathway of the Ligands. The free
energy landscapes of the four sets of simulations also indicate a
signiﬁcant role of the extracellular vestibule in driving the
binding process. ECL2, in particular, is often the ﬁrst point of
contact between the ligand and the receptors, as reported for
β-adrenergic receptors.27 The conformation of ECL2 is
diﬀerent in the two receptors. While a short helical turn is
present in both proteins toward the orthosteric binding pocket,
hosting F168 and E169 (A2aR) and the equivalent F171 and
E172 in A1R, a longer helical segment extending further into
the bulk solvent diﬀers in length and conformation (see Figure
1). In the binding path, we observe frequent interactions
between the ligands and the loops, especially with A151, A155,
A158, and K173 in A1R and K150 or K153 in A2aR. The
contact between ECL2 and the ligands likely helps preorient
the molecules toward the binding site, forcing the cores of the
molecules to lay on the loop surface, and funnelling the ligands
to the salt bridge at the entrance of the site (Figure 6), similar
Figure 4. Solvation of the 4-hydroxyphenyl or phenyl groups of the
ligands over the unbiased MD simulations, represented by the number
of water oxygen atoms within 4 Å from the moieties’ heavy atoms.
The plots illustrate the average solvation and its standard deviation as
a function of the RMSD of the ligand to an upright, 5IU4-like
conformation (see Figure 3). Conformations A and B show the
displacement of water molecules in the hydrophobic ECV pocket of
A1R by LUF5452.
Figure 5. Projection of the free energy landscapes onto Z-projection and XY-projection by reweighting.18 Boxes: Representative conformations of
the ligands bound to the main binding site of the receptors, LUF5452 interacting with the hydrophobic ECV pocket in A1R, and the two molecules
breaking the salt bridge at the entrance of the orthosteric site of the proteins.
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to what was observed by Dror et al.27 for β-adrenergic
receptors.
■ CONCLUSIONS
Our results suggest that a combination of three structural
diﬀerences of A1R and A2aR concur to the observed selectivity
of ZM241385, while leading to similar binding aﬃnities of
LUF5452. First, the salt bridge at the opening of the
orthosteric binding site of A1R and A2aR signiﬁcantly
inﬂuences the dynamical nature of the interaction between
the receptor and ligands. Second, albeit ZM241385 and
LUF5452 possess a similar binding mode, the presence of a
hydrophobic pocket in the binding site of A1R allows LUF5452
to adopt an alternative pose, displacing weakly interacting
water molecules in the region. Third, the desolvation of the 4-
hydroxyphenyl and phenyl groups of the two ligands leads to
the exploration of alternative conformations at the expense of
the water network that stabilizes them in the main binding
pose. While in A2aR this results in poor stabilization of
LUF5452, the hydrophobic pocket of A1R allows an eﬀective
desolvation of the group. Taken together, our ﬁndings conﬁrm
how the diﬀerential behavior of GPCR ligands arises from a
complex interplay of small but relevant structural and
dynamical diﬀerences and from diﬀerent solvation patterns.
The new insights on the molecular determinants of ligand
selectivity between A1R and A2aR provide a clear indication for
the structure-based rational design of selective drugs for these
receptors and possibly for other GPCRs.
■ METHODS
The crystal structures of the human A1 and A2a receptors were
downloaded from the Protein Data Bank (A1R: 5N2S,
7 A2aR:
5IU411). After correcting mutations and removing the
apocytochrome b562 (bRIL) inserted in the ICL3 loop or at
the N-terminus, missing residues were added with MOD-
ELLER 9.1928 and the proteins were embedded in a pre-
equilibrated POPC membrane. The membrane was then
aligned to the XY plane, resulting in the main axis of the
GPCRs and the Z axis being close to parallel.
The complexes were solvated with TIP3P water, and
chloride ions were added to balance the net charge. Ligands
were parametrized with the generalized AMBER force ﬁeld
(GAFF)29 and charges were calculated using Gaussian0930
with a 6-31G* basis set at the Hartree−Fock level. Protein,
water, and ion parameters were generated with AMBER14SB
force ﬁeld,31,32 and the phospholipid topology was downloaded
from LipidBook.33 The simulations were run using GRO-
MACS 5.1.434 with the PLUMED 2.3.1 plugin35 in the NPT
ensemble.
The metadynamics simulations were run using a parallel
tempering scheme in the 300−310 K temperature range.
During the production metadynamics runs, Gaussian hills were
deposited every 2 ps in the well-tempered scheme36 with a bias
factor of 15. The Gaussian width was set to 0.1 nm for the Z-
projection and XY-projection and to 0.033 nm for the salt
bridge distance. In the simulations where two CVs were biased,
the initial height was 1 kJ/mol, whereas in that biasing three
CVs it was set to 1.5 kJ/mol.
The exploration of the bulk water region by the ligand was
restrained with the use of a funnel-like restraint in order to aid
the convergence of the simulations.17,37
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Comparison of rat and human receptor sequences;
details of the setup of the molecular dynamics and
Figure 6. Representative binding or unbinding paths of the ligands, extracted from the PT-metaD simulations. The ligands need to break the salt
bridge at the entrance of the binding site in order to unbind. Extensive interactions with ECL2 are found before complete solvation of the ligands in
the fully unbound states.
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parallel-tempering metadynamics simulations; and fur-
ther information on the hydrophobic pocket of A1R, the
role of water in the orthosteric pocket of A1R, and on the
results of the metadynamics simulations (PDF)
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H.; Johansson, D.; Anckarsaẗer, H.; Westberg, L.; Eriksson, E.;
Halldner, L. A Study of the Possible Association Between Adenosine
A2A receptor Gene Polymorphisms and Attention-deficit Hyper-
activity Disorder Traits. Genes, Brain Behav. 2013, 12, 305−310.
(5) Chen, J.-F.; Eltzschig, H. K.; Fredholm, B. B. Adenosine
Receptors as Drug Targets - What Are the Challenges? Nat. Rev. Drug
Discovery 2013, 12, 265−286.
(6) Piirainen, H.; Ashok, Y.; Nanekar, R. T.; Jaakola, V.-P. Structural
Features of Adenosine Receptors: From Crystal to Function. Biochim.
Biophys. Acta, Biomembr. 2011, 1808, 1233−1244.
(7) Cheng, R. K. Y.; Segala, E.; Robertson, N.; Deflorian, F.; Dore,́
A. S.; Errey, J. C.; Fiez-Vandal, C.; Marshall, F. H.; Cooke, R. M.
Structures of Human A1 and A2A Adenosine Receptors with Xanthines
Reveal Determinants of Selectivity. Structure 2017, 25, 1275−1285.
(8) Draper-Joyce, C. J.; Khoshouei, M.; Thal, D. M.; Liang, Y.-l.;
Nguyen, A. T. N.; Furness, S. G. B.; Venugopal, H.; Baltos, J.-a.;
Plitzko, J. M.; Danev, R.; Baumeister, W.; May, L. T.; Wootten, D.;
Sexton, P. M.; Glukhova, A.; Christopoulos, A. Structure of the
Adenosine-bound Human Adenosine A1 Receptor - GI Complex.
Nature 2018, 558, 559−563.
(9) Glukhova, A.; Thal, D. M.; Nguyen, A. T.; Vecchio, E. A.; Jörg,
M.; Scammells, P. J.; May, L. T.; Sexton, P. M.; Christopoulos, A.
Structure of the Adenosine A1 Receptor Reveals the Basis for Subtype
Selectivity. Cell 2017, 168, 867−877.
(10) Ballesteros, J. A.; Weinstein, H. Methods in Neuroscience;
Academic Press, 1995; Vol. 25; pp 366−428.
(11) Segala, E.; Guo, D.; Cheng, R. K. Y.; Bortolato, A.; Deflorian,
F.; Dore,́ A. S.; Errey, J. C.; Heitman, L. H.; Ijzerman, A. P.; Marshall,
F. H.; Cooke, R. M. Controlling the Dissociation of Ligands from the
Adenosine A2A Receptor Through Modulation of Salt Bridge Strength.
J. Med. Chem. 2016, 59, 6470−6479.
(12) Jaakola, V.-P.; Griffith, M. T.; Hanson, M. A.; Cherezov, V.;
Chien, E. Y. T.; Lane, J. R.; IJzerman, A. P.; Stevens, R. C. The 2.6
Angstrom Crystal Structure of a Human A2A Adenosine Receptor
Bound to an Antagonist. Science 2008, 322, 1211−1217.
(13) Dore,́ A. S.; Robertson, N.; Errey, J. C.; Ng, I.; Hollenstein, K.;
Tehan, B.; Hurrell, E.; Bennett, K.; Congreve, M.; Magnani, F.; Tate,
C. G.; Weir, M.; Marshall, F. H. Structure of the Adenosine A2A
Receptor in Complex with ZM241385 and the Xanthines XAC and
Caffeine. Structure 2011, 19, 1283−1293.
(14) Liu, W.; Chun, E.; Thompson, A. A.; Chubukov, P.; Xu, F.;
Katritch, V.; Han, G. W.; Roth, C. B.; Heitman, L. H.; IJzerman, A. P.;
Cherezov, V.; Stevens, R. C. Structural Basis for Allosteric Regulation
of GPCRs by Sodium Ions. Science 2012, 337, 232−236.
(15) de Zwart, M.; Vollinga, R. C.; Beukers, M. W.; Sleegers, D. F.;
von Frijtag Drabbe Künzel, J. K.; de Groote, M.; Ijzerman, A. P.
Potent Antagonists for the Human Adenosine A2b Receptor.
Derivatives of the Triazolotriazine Adenosine Receptor Antagonist
ZM241385 with High Affinity. Drug Dev. Res. 1999, 48, 95−103.
(16) Saleh, N.; Saladino, G.; Gervasio, F. L.; Haensele, E.; Banting,
L.; Whitley, D. C.; Sopkova-de Oliveira Santos, J.; Bureau, R.; Clark,
T. A Three-site Mechanism for Agonist/Antagonist Selective Binding
to Vasopressin Receptors. Angew. Chem., Int. Ed. 2016, 55, 8008−
8012.
(17) Saleh, N.; Ibrahim, P.; Saladino, G.; Gervasio, F. L.; Clark, T.
An Efficient Metadynamics-based Protocol to Model the Binding
Affinity and the Transition State Ensemble of G-protein-coupled
Receptor Ligands. J. Chem. Inf. Model. 2017, 57, 1210−1217.
(18) Tiwary, P.; Parrinello, M. A Time-independent Free Energy
Estimator for Metadynamics. J. Phys. Chem. B 2015, 119, 736−742.
(19) Sugita, Y.; Okamoto, Y. Replica-exchange Molecular Dynamics
Method for Protein Folding. Chem. Phys. Lett. 1999, 314, 141−151.
(20) Laio, A.; Parrinello, M. Escaping Free-Energy Minima. Proc.
Natl. Acad. Sci. U. S. A. 2002, 99, 12562−12566.
(21) Guo, D.; Xia, L.; van Veldhoven, J. P. D.; Hazeu, M.; Mocking,
T.; Brussee, J.; IJzerman, A. P.; Heitman, L. H. Binding Kinetics of
ZM241385 Derivatives at the Human Adenosine A2A Receptor.
ChemMedChem 2014, 9, 752−761.
(22) Goodford, P. J. A computational procedure for determining
energetically favorable binding sites on biologically important
macromolecules. J. Med. Chem. 1985, 28, 849−857.
(23) Mason, J. S.; Bortolato, A.; Congreve, M.; Marshall, F. H. New
Insights from Structural Biology into the Druggability of G Protein-
coupled Receptors. Trends Pharmacol. Sci. 2012, 33, 249−260.
(24) Mason, J. S.; Bortolato, A.; Weiss, D. R.; Deflorian, F.; Tehan,
B.; Marshall, F. H. High End GPCR Design: Crafted Ligand Design
and Druggability Analysis Using Protein Structure, Lipophilic
Hotspots and Explicit Water Networks. In Silico Pharmacol. 2013, 1,
23.
(25) Guo, D.; Pan, A. C.; Dror, R. O.; Mocking, T.; Liu, R.;
Heitman, L.; Shaw, D. E.; IJzerman, A. P. Molecular Basis of Ligand
Dissociation from the Adenosine A2A Receptor. Mol. Pharmacol. 2016,
89, 485−491.
(26) Jespers, W.; Schiedel, A. C.; Heitman, L. H.; Cooke, R. M.;
Kleene, L.; van Westen, G. J. P.; Gloriam, D. E.; Müller, C. E.; Sotelo,
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